Role of manidipine in the management of patients with hypertension

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 6, 2004, Pages 815-827

  Tikhonoff, Valérie ^a   Mazza, Alberto ^a   Casiglia, Edoardo ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Calcium channel blocker; Diabetic patients; Elderly; Hypertension; Manidipine; Renal afferent vasodilation; Renal efferent vasodilation

Indexed keywords

AMIODARONE; AMLODIPINE; AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DELAPRIL; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; LISINOPRIL; LOSARTAN; MANIDIPINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PLACEBO; VERAPAMIL; VOLTAGE GATED CALCIUM CHANNEL;

ANKLE EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DIZZINESS; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; FLUSHING; GLUCOSE METABOLISM; HEADACHE; HEART PALPITATION; HUMAN; KIDNEY DISEASE; METABOLIC DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; STROKE; VASODILATATION;

ADULT; AGED; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE MONITORING, AMBULATORY; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 8644288187     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.6.815     Document Type: Review

References (111)

1. Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Drugs 58, 579-587 (1999).
2. Staessen JA, Wang JG, Thijs L. Calcium channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am. J. Hypertens. 15, S85-S93 (2002).
3. Messerli FH. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am. J. Hypertens. 15, S94-S97 (2002).
4. Angelico P, Guarnieri N, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J. Pharm. Pharmacol. 51, 709-714 (1999).
5. Van Zvieten PA. The pharmacological prospectives of lipophilic calcium antagonists. Blood Press. 2(Suppl.), 5-9 (1998 ).
6. Lund-Johansen P, Stranden E, Helberg S et al. Quantification of leg edema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 21, 1003-1010 (2003).
7. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 15, 932-940 (2002).
8. Okabe K, Terada K, Kitamura K et al. Selective and long-lasting inhibitory actions of the dihydropyridine derivative, CV4093, on calcium currents in smooth muscle cells of the rabbit pulmonary artery. J. Pharmacol. Exp. Ther. 243, 703-710 (1987).
9. Martindale: The Complete Drug Reference, 32nd Edition. Parfitte K (Ed.). Pharmaceutical Press, MA, USA (1999).
10. 2+ increase in GH3 cells. Eur. J. Pharmacol. 376, 169-178 (1999).
11. Van Zwieten PA, Pfaffendorf M. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J. Hypertens. 11, S3-S8 (1993).
12. Fogari R, Zoppi A, Lusardi P, Muggellini A. Efficacy and tolerability of manidipine hydrochloride in the long-term treatment of mild-to-moderate hypertension. Blood Press. 5, S24-S28 (1996).
13. Nagaoka A. Pharmacologic characteristics of a new calcium antagonist, manidipine: benefical effects on renal circulation and vascular changes. Am. Heart J. 125, 560-565 (1993).
14. Nakaya H, Hattori Y, Nakao Y, Kanno M. Cardiac versus vascular effects of a new dihydropyridine derivative, CV-4093. In vitro comparison with other calcium antagonists. Eur. J. Pharmacol. 146, 35-43 (1998).
15. Shibouta Y, Kitayoshi T, Kitoh G, Nishikawa K. Calcium channel-blocking action of franidipine hydrochloride (CV-4093.2HCl) in vitro and in vivo. Jpn J. Pharmacol. 48, 463-472 (1988).
16. Nagaoka A, Kito G, Nagai Y. Antihypertensive action, calcium channel-blocking action and receptor binding activity of manidipine hydrochloride in experimental animals (in Japanese). Jpn Pharmacol. Ther. 18, 11-20 (1990).
17. Pfaffendorf M, Mathy MJ, van Zwieten PA. Effects of manidipine and other calcium antagonists on rat renal arcuate arteries. Am. Heart J. 125, 571-577 (1993).
18. Roth M, Keul R, Perruchoud AP, Block LH. Manidipine affects rPDF-BB-induced gene transcription of low-density lipoprotein receptors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in human mesangial cells. Am. Heart J. 125, 598-603 (1993).
19. 2+-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. J. Mol. Cell. Cardiol. 27, 2295-2302 (1995).
20. Fukuzawa M, Satoh J, Ohta S et al. Modulation of tumor necrosis factor-α production with a hypertensive drugs. Immunopharmacology 48, 65-74 (2000).
21. Kakihana M, Suno M, Nagaoka A. Antihypertensive effect of CV-4093.2HCL, a new calcium antagonist, in three rat models of hypertension. Jpn J. Pharmacol. 48, 223-228 (1988).
22. Tanabe M, Kawazoe K, Kito G et al. Effects of manidipine hydrochloride (CV-4093.2HCl) on systemic hemodynamics, cardiac function and plasma renin activity in conscious renal hypertensive dogs. Jpn Pharmacol. Ther. 17, 779-788 (1989).
23. Tanabe M, Kawazoe K, Kito G et al. Effects of manidipine hydrochloride (CV-4093 [2HCI]) on hemodynamics and cardiac function in conscious normotensive dogs. Jpn Pharmacol. Ther. 17, 55-66 (1989).
24. Kajino M, Wada Y, Nagai Y, Nagaoka A, Meguro K. Synthesis and biological activities of optical isomers of 2-(4-diphenylmethyl-1-piperazinyl)ethyl methyl 1,4-dihydro-2,6-dimethyl-4(3-nitrophenyl)-3,5-pyridibedicarboxylate (manidipine) dihydrochloride. Chem. Pharm. Bull. 37, 2225-2228 (1989).
25. Takahashi K, Katoh T, Fukunaga M et al. Studies on the glomerular microcirculatory actions of manidipine and its modulation of the systemic and renal effects of endothelin. Am. Heart J. 125, 609-619 (1993).
26. Takabatake T, Ushiogi Y, Ise T et al. Effect of calcium antagonist, manidipine hydrochloride, on renal hemodynamics and tubuloglomerular feedback in spontaneously hypertensive rats. Am. Heart J. 125, 578-581 (1993).
27. Hayashi K, Ozawa Y, Fujiwara K et al. Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am. J. Nephrol. 23, 229-244 (2003).
28. Hansen PB, Jensen BL, Andreasen D, Skott O. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ. Res. 89, 630-638 (2001).
29. Arima S, Ito S, Omata K et al. Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int. 55, S132-S134 (1996).
30. Nagaoka A, Shibota M, Hamajo K. Effects of a new dihydropyridine derivate, CV-4093.2HCL, on renal hemodynamics; in spontaneously hypertensive rats. Jpn J. Pharmacol. 51, 25-35 (1989).
31. Kobayashi S, Hishida A. Manidipine attenuates a progressive renal injury in remnant kidneys of rats. Blood Press. 3, 80-84 (1992).
32. Kobayashi S, Hishida A. Effects of a calcium antagonist, manidipine, on progressive renal injury associated with mild hypertension in remnant kidneys. J. Lab. Clin. Med. 125, 572-580 (1995).
33. Fujimaki M, Nagase M, Uchida S. Long-term effect of manidipine on renal function and structure in uninephrectomized spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 24, 506-512 (1997).
34. Reams GP, Villarreal D, Wu Z et al. An evaluation of the renal protective effect of manidipine in the uninephrectomized spontaneously hypertensive rat. Am. Heart J. 125, 620-625 (1993).
35. Sabbatini M, Vitaioli L, Baldoni E et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 294, 948-954 (2000).
36. Sabbatini M, Leonardi A. Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 35, 775-779 (2000).
37. 2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 39, 39-48 (2002).
38. Nagaoka A. Shibota M. Natriuretic action of manidipine hydrochloride, a new calcium channel blocker, in spontaneously hypertensive rats. Jpn J. Pharmacol. 51, 299-301 (1989).
39. He H, Tamaki T, Aki Y et al. Effects of the calcium antagonist manidipine on renal hemodynamics and function in dogs: comparison with nifedipine. Blood Press. 3, 68-74 (1992).
40. Nayler WG, Panagiotopoulos S. The antiatherosclerotic effect of the calcium antagonists and their implications in hypertension. Am. Heart J. 125, 626-629 (1993).
41. phox and HO-1: relevance for antihypertensive and antiremodelling effects. J. Cardiovasc. Pharmacol. 43(4), 531-538 (2004).
42. Nagaoka A. Pharmacological prevention of cerebral stroke in stroke-prone spontaneously hypertensive rats. J. Hypertens. 4, S523-S525 (1986).
43. Sabbatini M, Tomassoni D, Amenta F. Hypertensive brain damage: comparative evaluation of protective effect of treatment with dihydropyridine derivates in spontaneously hypertensive rats. Mech. Ageing Dev. 122, 2085-2105 (2001).
44. 2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech. Ageing Dev. 122, 795-809 (2001).
45. Sabbatini M, Tomassoni D, Di Tullio MA, Amenta F. Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clin. Exp. Hypertens. 24, 727-740(2002).
46. Yoshhiyama M, Takeuchi K, Kim S et al. Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricutar hypertrophy. Jpn Circ. J. 62, 47-52 (1998).
47. 2+ antagonists on ventricle hypertophy and coronary changes in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 41, 544-552 (2003).
48. Masanori S, Toshihiko S, Koji H et al. Orally administrated benidipine and manidipine prevent ischemia-reperfusion injury in the rat heart. Circ J. 68, 241-246 (2004).
49. Kasai Y, Sheu HL, Yabe T, Saso S, Abe K. Acute effect of manidipine on renal blood flow measured by pulse-Doppler flowmeter in normal subjects. Blood Press. 3, S102-S105 (1992).
50. Celentano A, Crivaro M, Perticone F et al. Antihypertensive effect of manidipine: 24-h monitoring evaluation and Doppler-echocardiographic remarks. Blood Press. 5, S29-S35 (1996).
51. Fogari R, Zoppi A. Lusardi P et al. Evaluation by 24-h ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild-to-moderate essential hypertension: a double-blind, randomized, parallel group, placebo-controlled study. Blood Press. 5, S16-S23 (1996).
52. Mancia G, Omboni S, Agabiti-Rosei E et al. Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. J. Cardiovasc. Pharmacol. 35, 926-931 (2000).
53. Fogari R, Zoppi A, Mugellini A et al. Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives. Cardiovasc. Drugs Ther. 13, 243-248 (1999).
54. Fogari R, Zoppi A, Corradi L et al. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J. Hypertens. 18, 1871-1875 (2000).
55. Zanchetti A, Omboni S, La Commare P et al. Efficacy, tolerability and impact on quality of life and long-term treatment with manidipine or amlodipine in patients with essential hypertension. J. Cardiovasc. Pharmacol. 38, 642-650 (2001).
56. Atarashi K, Takagi M, Minami M et al. Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with noninsulin-dependent diabetes mellitus. Blood Press. 1, S130-S134 (1992).
57. Mancia G, Omboni S, Agabiti-Rosei E et al. Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. J. Cardiovasc. Pharmacol. 35, 926-931 (2000).
58. Lai Y-H, Guh J-Y, Chen H-C et al. Effects of manidipine hydrochloride on blood pressure in hypertensive patients - a comparison with nifedipine retard. Kaohsiung J. Med. Sci. 9, 625-631 (1993).
59. Takabatake T, Ohta H, Sasaki T et al. Renal effects of manidipine hydrochloride: a new calcium antagonist in hypertensive patients. Eur. J. Clin. Pharmacol. 45, 321-325 (1993).
60. Yamakado M, Shimomura H, Maehata E. Renoprotection of calcium antagonist: effect of manidipine on urinary microalbumin excretion and lipid peroxidation. Am. J. Hypertens. 9, 154 (1996).
61. Shiba T, Inoue M, Tada H et al. Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes mellitus associated nephropathy. Diabetes Res. Clin. Pract. 47, 97-104 (2000).
62. Bellinghieri G, Mazzaglia G, Savica. V, Santoro D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren. Fail. 25(5), 681-689 (2003).
63. Marusaki S, Shimamoto K, Komura H et al. Effects of manidipine on renal sodium and calcium handling in patients with mild essential hypertension. Ther. Res. 14(7), 128-133 (1993).
64. Karges JR, Mark BE, Stikeleather SJ, Worrell TW. Concurrent validity of upper-extremity volume estimates: comparison of calculated volume derived from girth measurements and water displacement volume. Phys. Ther. 83, 134-145 (2003).
65. Fogari R, Malamani GD, Savino S et al. Effects of different dihydropyridine calcium antagonists on pretibial subcutaneous tissue pressure in hypertensive patients. Am. J. Hypertens. 11, 114 (1998).
66. Fogari R, Malamani GD, Zoppi A et al. Manidipine has less edemigenous potential than amlodipine. J. Hypertens. 18, S154-S155 (2000).
67. Casiglia E, Mazza A, Tikhonoff V, Pessina AC. Therapeutic profile of manidipine and lercanidipine in hypertensive patients. Am. J. Hypertens. (2004) (In press).
68. Rosillon D, Stockis A, Poli G et al. Food effect on the oral bioavailability of manidipine: single dose, randomized, crossover study in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 23, 197-202 (1998).
69. Tateno M. Pharmacokinetic study of CV-4093 (2 HCl) at single dose on healthy subjects. Rinsho Iyaku 5, 1765-1777 (1989).
70. Deroubaix X, Lins RL, Lens S et al. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls. Int. J. Clin. Pharmacol. Ther. 36, 386-391 (1998).
71. Chiesi Farmaceutici SPA/Takeda Italia Farmaceutici. Summary of product characteristics. Chiesi Farmaceutici SPA/Takeda Italia Farmaceutici (2000).
72. Katoh M, Nakajima M, Shimada N et al. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug interactions. Eur. J. Clin. Pharmacol. 55(11-12), 843-852 (2000).
73. Hashimoto Y, Shimizu A, Kuroda T et al. Effect of dihydropyridine calcium channel blockers on the plasma digoxin level. Jpn J. Clin. Pharmacol. Ther. 27(4), 665-671 (1996).
74. 2+ anatgonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur. J. Pharm. Sci. 16(3), 159-165 (2002).
75. Stockis A, Gengler C, Goethals F et al. Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers. Arzneimittelforschung 53(9), 627-634 (2003).
76. Ogihara T. Practitioner's trial on the efficacy of Antihypertensive Treatment in the Elderly-Hypertension (the PATE-Hypertension study) in Japan. Am. J. Hypertens. 13(5), 461-467 (2000).
77. Ogihara T, Nakagawa M, Ishikawa H et al. Effect of manidipine, a novel calcium channel blocker, on quality of life in hypertensive patients. Blood Press. 3, S135-S139 (1992).
78. Hase MI, Hase MO, Igawa S et al. Reduction of left ventricular mass by manidipine hydrochloride. Am. J. Hypertens. 11(4), A81 (1998).
79. Nagasawa K, Kitamoto K, Nagasawa T. A 3-year long-term evaluation of the efficacy and safety of manidipine hydrochloride (Calslot tablet) in the elderly with essential hypertension: a multicenter collaborative study. Rinsho Kenkyu 74(10), 2630-2638 (1997).
80. Kaneko Y, Fukiyama K, Iimura O et al. Clinical study of manidipine hydrochloride in essential hypertension: a double-blind controlled study with nicardipine hydrochloride. J. Clin. Exp. Med. 151(8), 471-492 (1989).
81. Tomiyama H, Kimura Y, Saluma Y et al. Effects of an ACE inhibitor and calcium channel blocker on cardiovascular autonomic nervous system and carotid distensibility in patients with mild-to-moderate hypertension. Am. J. Hypertens. 11, 682-689 (1998).
82. Saku K, Zhang B, Hirata K et al. Effects of manidipine and delapril on serum lipids, lipoproteins, and apolipoproteins in-patients with mild-to-moderate essential hypertension: a randomized trial with 1-year follow-up. Clin. Ther. 14, 813-820 (1992).
83. Karpati P, Alberici M, Tocci G et al. Long-term tolerability and efficacy of the fixed combination of manidipine and delapril in pateints with essential hypertension. High Blood Press. Cardiovasc. Prev. 10(2), 81-86 (2003).
84. Mizuno Y, Haga H, Takahashi M et al. Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients with renal disorders. Blood Press. 3, S119-S123 (1992).
85. Saruta T, Suzuki H. Efficacy of manidipine in the treatment of hypertension with renal impairment: a multicenter trial. Am. Heart J. 125(2), 630-634 (1993).
86. Crivaro M, Celentano A, Palmieri V et al. Mild arterial hypertension and impaired glucose tolerance: short-term effects of manidipine hydrochloride. Adv. Ther.13(6), 365-372 (1996).
87. Oliviero M, Turco S, Tammaro P et al. Manidipina versus amlodipina in Type II diabetic patients with hypertension: comparison in double-blind. Diabetologia 41(1), A340 (1998) (Abstract).
88. Fogari R, Mugellini A, Zoppi A et al. Effect of manidipine and lisinopril on albuminuria and ventricular mass in diabetic hypertensive patients with microalbuminuria. Am. J. Hypertens. 15(4), A22 (2002) (Abstract).
89. Suzuki S, Ohtomo M, Satoh Y et al. Effect of manidipine and delapril on insulin sensitivity in Type 2 diabetic patients with essential hypertension. Diabetes Res. Clin Pract. 33, 43-51 (1996 ).
90. Iimura O, Shimamoto K, Masuda A et al. Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives. J. Diabetes Complicat. 9, 215-219 (1995).
91. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. J. Am. Med. Assoc. 289, 2560-2572 (2003).
92. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1053 (2003).
93. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). Br. Med. J. 328, 634-640 (2004).
94. Staessen JA, Fagard R, Thijs L et al. Randomized double-blind comparison of placebo and active treatment of older patients with isolated systolic hypertension. The Syst-Eur Trial Investigators. Lancet 350, 757-764 (1997).
95. Tuomilehto J, Rasyenyte D, Birkenhager WH et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in European Trial Investigators. N. Engl. J. Med. 340, 677-684 (1999).
96. Voyaki SM, Staessen JA, Thijs L et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in European (Syst-Eur) Trial Investigators. J. Hypertens. 19, 511-519 (2001).
97. Forette F, Amery A. Staessen JA et al. Is prevention of vascular dementia possible? The Syst-Eur Vascular Dementia project. Aging 3, 373-382 (1991).
98. Seux ML, Thijs L, Forette F et al. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur vascular dementia project J. Hypertens. 16, 963-969 (1998).
99. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension (Syst-Eur) Trail. Lancet 352, 1347-1351 (1998).
100. Pitt B, Byington RP, Fuberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 102, 1503-1510 (2000).
101. Staessen JA. Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358, 1305-1315 (2001).
102. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a qualitative overview updated until 1 March 2003. J. Hypertens. 21, 1055-1076 (2003).
103. Pahor M, Guralnik JM, Furberg CD et al. Risk of GI hemorrhage with calcium antagonists in hypertensive people over 67 years old. Lancet 347, 1061-1065 (1996).
104. Jick H, Jick S, Derby LE et al. Calcium channel blockers and risk of cancer. Lancet 349, 525-528 (1997).
105. Pstay BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. J. Am. Med. Assoc. 277, 739-745 (1997).
106. Furberg CD, Psaty BM. Calcium antagonists: not appropriate as first-line antihypertensive agents. Am. J. Hypertens. 9(2), 122-125 (1996).
107. Salvetti A, Mattei P, Sudano I. Renal protection and antihypertensive drugs: current status. Drugs 57(5), 665-693 (1999).
108. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood prressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Traterrent (HOT) randomized trial. HOT Study Group. Lancet 351, 1755-1762 (1998).
109. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
110. Fogari R, Malamani G, Derosa G et al. Effect of delapril addition to manidipine on ankle edema and subcutaneous tissue pressure in hypertensive patients. Am. J. Hypertens. 16, A113 (2003) (Abstract).
111. Mugellini A, Preti P, Zoppi A et al. Effect of delapril-mandipine combination vs. irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with Type II diabetes mellitus. J. Hum. Hypertens. 18(10), 687-691 (2004).